Dr. Jennifer A. Crozier

Hematology
Baptist MD Anderson Cancer Center
1301 W Palm Ave, 
Jacksonville, FL 
Clinical Trials:Currently Recruiting for 1 Trial
12 Years of Experience
Baptist MD Anderson Cancer Center
1301 W Palm Ave, 
Jacksonville, FL 

Overview

Jennifer Crozier is a Hematologist practicing medicine in Jacksonville, Florida. She has been practicing medicine for over 12 years.

Her clinical expertise encompasses Menopause, Monoclonal Gammopathy of Undetermined Significance (MGUS), Schnitzler Syndrome, and Anemia.

She is actively involved in clinical research, co-authoring 21 peer reviewed articles and participating in 10 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in FL

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D

Locations

Baptist MD Anderson Cancer Center
1301 W Palm Ave, Jacksonville, FL 32254

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients With DCIS Following Breast Conserving Therapy
A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients With DCIS Following Breast Conserving Therapy
Enrollment Status: Recruiting
Publish Date: April 17, 2026
Intervention Type: Other, Device
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)
A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)
Enrollment Status: Active_not_recruiting
Publish Date: August 18, 2026
Intervention Type: Drug, Other
Study Drug: Ribociclib
Study Phase: Phase 3
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: July 27, 2026
Intervention Type: Drug
Study Drugs: Capecitabine, Carboplatin, Cisplatin
Study Phase: Phase 3
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Enrollment Status: Active_not_recruiting
Publish Date: July 23, 2026
Intervention Type: Drug
Study Drugs: tucatinib, T-DM1
Study Phase: Phase 3
ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
Enrollment Status: Active_not_recruiting
Publish Date: June 05, 2026
Intervention Type: Drug
Study Drugs: Fulvestrant, Anastrozole
Study Phase: Phase 3
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Enrollment Status: Completed
Publish Date: April 08, 2026
Intervention Type: Other, Drug
Study Drugs: Cisplatin, Veliparib
Study Phase: Phase 2
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Drug
Study Drugs: tucatinib, capecitabine, trastuzumab
Study Phase: Phase 2
View 9 Less Clinical Trials

21 Total Publications

Elacestrant in Combination with Everolimus for Estrogen Receptor-Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATE.
Elacestrant in Combination with Everolimus for Estrogen Receptor-Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATE.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 17, 2026
Similar Doctors
Expertise in
26
conditions
Dr. Steven Attia
Hematology | Oncology
Expertise in
26
conditions
Dr. Steven Attia
Hematology | Oncology
Referral may be required

FL - Cancer

4500 San Pablo Rd S, 
Jacksonville, FL 
 (18.0 miles away)
904-914-5419
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Steven Attia is a Hematologist and an Oncologist practicing medicine in Jacksonville, Florida. Dr. Attia is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Synovial Sarcoma, Liposarcoma, Angiosarcoma, and Thyroidectomy. Dr. Attia is currently accepting new patients.

Expertise in
31
conditions
Dr. James Foran
Hematology | Oncology
Expertise in
31
conditions
Dr. James Foran
Hematology | Oncology
Referral may be required

Mayo Clinic Hematology & Oncology

4500 San Pablo Rd S, 
Jacksonville, FL 
 (18.0 miles away)
904-953-7188
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

James Foran is a Hematologist and an Oncologist practicing medicine in Jacksonville, Florida. Dr. Foran is highly rated in 31 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Aspiration, and Colonoscopy. Dr. Foran is currently accepting new patients.

Expertise in
21
conditions
Dr. Sikander Ailawadhi
Hematology | Oncology
Expertise in
21
conditions
Dr. Sikander Ailawadhi
Hematology | Oncology
Referral may be required

Mayo Clinic Hematology & Oncology

4500 San Pablo Rd S, 
Jacksonville, FL 
 (18.0 miles away)
904-953-7188
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sikander Ailawadhi is a Hematologist and an Oncologist practicing medicine in Jacksonville, Florida. Dr. Ailawadhi is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Chronic Lymphocytic Leukemia (CLL), Bone Marrow Aspiration, and Colonoscopy. Dr. Ailawadhi is currently accepting new patients.

Frequently Asked Questions about Dr. Jennifer A. Crozier

How do I make an appointment with Dr. Jennifer A. Crozier?

You can book an appointment with Dr. Jennifer A. Crozier by calling their office at 904-202-7300. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jennifer A. Crozier a top-rated expert for Menopause?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jennifer A. Crozier is classified as an Experienced expert for Menopause, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jennifer A. Crozier specialize in?

While Dr. Jennifer A. Crozier is a Hematology, they have specific expertise in Menopause, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Schnitzler Syndrome. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Jennifer A. Crozier participate in research or clinical trials?

Yes. Dr. Jennifer A. Crozier has published 21 articles and abstracts on conditions like Menopause. You can view a list of Dr. Jennifer A. Crozier's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jennifer A. Crozier accept my insurance?

Dr. Jennifer A. Crozier accepts most major insurance plans, including Anthem BCBS and Medicare. We recommend calling the office directly at 904-202-7300 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Crozier's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile